Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

著者: Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, Jae‐Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David I. Quinn, Elisabeth I. Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary S. Campbell, Bradley A. McGregor, Arjun Vasant Balar - The Lancet 2021 被引用: 267